Live price temporarily unavailable.
Price history
Seres Therapeutics (MCRB) is a Health Care company. Latest news and coverage below.
IPO: June 26, 2015 · $18.00 offering · NASDAQ · View IPO details →
Seres Therapeutics revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $21.8M | $32.1M | $28.3M | $34.5M | $33.2M | $144.9M | $7.13M | $0 | $0 | $789.0K |
| Growth (year over year) | — | +47.5% | −11.9% | +22.1% | −3.7% | +336.3% | −95.1% | −100.0% | — | — |
| Operating income | −$92.8M | −$91.4M | −$100.3M | −$71.9M | −$88.1M | −$64.5M | −$179.9M | −$195.1M | −$121.3M | −$94.0M |
| Operating margin | −426.5% | −284.7% | −354.8% | −208.3% | −265.3% | −44.5% | −2524.0% | — | — | −11910.1% |
| Net income | −$91.6M | −$89.4M | −$98.9M | −$70.3M | −$89.1M | −$65.6M | −$250.2M | −$113.7M | $136.0K | $5.70M |
| Net margin | −420.7% | −278.4% | −350.0% | −203.7% | −268.3% | −45.2% | −3509.5% | — | — | 721.9% |
| EPS (diluted) | −$920.00 | −$884.00 | −$972.00 | −$496.00 | −$22.40 | −$14.40 | −$46.20 | −$17.77 | $0.00 | $0.64 |
| Balance sheet | ||||||||||
| Cash and equivalents | $54.5M | $36.1M | $85.8M | $65.1M | $116.0M | $180.0M | $163.0M | $128.0M | $30.8M | $45.8M |
| Total assets | $272.6M | $189.5M | $120.5M | $132.4M | $342.9M | $354.9M | $348.8M | $358.6M | $139.8M | $138.2M |
| Total liabilities | $140.0M | $128.8M | $168.5M | $180.8M | $168.2M | $223.4M | $338.0M | $403.5M | $126.0M | $94.0M |
| Long-term debt | — | — | — | $25.0M | $25.0M | $24.1M | $50.0M | $110.0M | — | — |
| Shareholders' equity | $132.6M | $60.7M | −$48.0M | −$48.3M | $174.8M | $131.5M | $10.8M | −$44.9M | $13.8M | $44.2M |
| Cash flow | ||||||||||
| Operating cash flow | $43.9M | −$75.5M | −$62.9M | −$76.5M | −$93.6M | $6.69M | −$228.8M | −$117.4M | −$148.6M | $1.12M |
| Capital expenditure | $21.5M | $4.68M | $1.94M | $1.00M | $591.0K | $9.57M | $9.82M | $7.97M | $380.0K | $252.0K |
| Free cash flow | $22.4M | −$80.2M | −$64.8M | −$77.5M | −$94.2M | −$2.88M | −$238.6M | −$125.3M | −$149.0M | $865.0K |
| Share buybacks | — | $33.0K | — | — | — | — | — | — | — | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $0 | $351.0K | — | $358.0K | $736.0K |
| Growth (year over year) | −100.0% | — | — | — | — | — | — | — |
| Operating income | −$29.2M | — | −$27.2M | −$24.9M | −$22.5M | — | −$20.9M | −$21.3M |
| Operating margin | — | — | — | — | −6403.7% | — | −5839.9% | −2890.4% |
| Net income | $88.8M | — | $32.7M | −$19.9M | $8.20M | — | −$19.9M | $4.58M |
| Net margin | — | — | — | — | 2337.3% | — | −5562.3% | 622.4% |
| EPS (diluted) | $11.63 | — | $3.75 | −$2.27 | $0.94 | — | −$2.08 | $0.47 |
| Balance sheet | ||||||||
| Cash and equivalents | $66.8M | $30.8M | $58.8M | $45.4M | $47.6M | $45.8M | $29.8M | $15.6M |
| Total assets | $178.7M | $139.8M | $164.2M | $143.8M | $143.5M | $138.2M | $117.6M | $101.6M |
| Total liabilities | $154.8M | $126.0M | $113.7M | $110.8M | $99.8M | $94.0M | $91.1M | $67.1M |
| Shareholders' equity | $23.9M | $13.8M | $50.5M | $33.0M | $43.7M | $44.2M | $26.5M | $34.5M |
| Cash flow | ||||||||
| Operating cash flow | −$34.7M | — | $26.9M | −$13.3M | $2.21M | — | −$16.4M | −$22.4M |
| Capital expenditure | $129.0K | — | $34.0K | $181.0K | $8.00K | — | $0 | $0 |
| Free cash flow | −$34.8M | — | $26.9M | −$13.5M | $2.20M | — | −$16.4M | −$22.4M |
From Seres Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About Seres Therapeutics
David Berry is an American entrepreneur and business executive. He has co-founded Valo Health, Seres Therapeutics, Indigo Agriculture, Axcella Health, and contributed to the early development of Moderna.
Source: Wikipedia — David Berry (inventor)
- Headquarters
- Cambridge, Massachusetts From SEC filings, Oct 2026
Recent News
No recent news mentioning Seres Therapeutics in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International